MRK · News · 20260901N

Competition and Market Share

Merck & Co., Inc. · 2026-09-01 · Importance 17 · Surprise 24

BriaCell Therapeutics is advancing a personalized whole-cell melanoma immunotherapy vaccine toward clinical development. Its off-the-shelf approach is positioned as potentially reducing treatment costs and development timelines versus individualized therapies. BriaCell’s whole-cell technology represents an alternative to Merck and Moderna’s mRNA-based melanoma vaccine approach in the skin-cancer market.

Key facts

• Merck's recent success in melanoma trials has rekindled analyst interest in mRNA technology. source